Growth Partner and Docquity Launch Landmark Medically Supervised and Technology-Enabled Umrah Program
Growth Partner and Docquity launch a technology-enabled, doctor-accompanied pilgrimage programme for pilgrims with health conditions — a global first in inclusive Umrah tourism. RIYADH, Saudi Arabia, May 19, 2026 /PRNewswire/ -- Growth Partner and Docquity today announced the launch of the world's first medically supervised, technology-enabled Umrah programme, working alongside ecosystem initiatives supported...
Fujitsu, SMBC Group and SoftBank agree on alliance to build Japan-made platform for sustainable healthcare
Companies aim to extend healthy life expectancy, optimize management of healthcare institutions, and curb national healthcare costs Sumitomo Mitsui Financial Group, Inc.Fujitsu LimitedSoftBank Corp. TOKYO, May 19, 2026 /PRNewswire/ -- Fujitsu Limited (Fujitsu), Sumitomo Mitsui Financial Group, Inc. (SMBC Group), and SoftBank Corp. (SoftBank) announced they entered into a basic agreement regarding a...
BIOTRONIK, Charité, and German Heart Center Foundation Announce Partnership to Advance Digital Cardiology
Strategic Initiative Strengthens Berlin as Europe's Hub of Digital Cardiology BERLIN, May 19, 2026 /PRNewswire/ -- BIOTRONIK, die Charité – Universitätsmedizin Berlin, and the German Heart Center Foundation today announced a research and innovation partnership focused on advancing digital and translational cardiology. The collaboration will bring together world-class clinical cardiovascular expertise at...
Caliway Makes First ECO 2026 Oral Presentation on Preclinical Data of CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies, Attracting Strong Interest from International Experts and Global Pharmaceutical Companies for...
CBL-514, when combined separately with two leading GLP-1R-based weight-loss therapies, semaglutide and tirzepatide, demonstrated enhanced weight loss, attenuated post-discontinuation weight regain, and greater reductions in subcutaneous and visceral fat in animal studies. The presentation also marked the first disclosure at an international congress of CBL-514's potential to improve liver metabolic indicators. ...
Leads Biolabs’ PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC
NANJING, China, May 19, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), has received approval from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to initiate a pivotal Phase III clinical trial for the first-line...
Innovent Showcased Clinical and Preclinical Results of Next-Generation Autoimmune and Ophthalmology Pipeline at the 2026 ATS and ARVO Conferences
SAN FRANCISCO and SUZHOU, China, May 19, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that it will present multiple clinical and preclinical data from IBI3002(IL-4Rα/TSLP), IBI3038(IGF-1R/IL-6), IBI3031(IGF-1R/TSHR) at the 2026...
Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases
Financing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investors SCGC and Oriza Proceeds will advance multi-asset pipeline including AC-101, a leading RIPK2 inhibitor for Ulcerative Colitis NEW YORK and SUZHOU, China, May 19, 2026 /PRNewswire/ -- Accro Bioscience Inc. ("Accro Bioscience"), a clinical-stage biotechnology company pioneering the development of novel therapeutics that...
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) has completed patient enrolment. Maximum dose reached with no dose-limiting toxicities observed. TLX101-Tx is also the subject of a pivotal trial, IPAX BrIGHT, which is actively dosing patients with recurrent glioblastoma. MELBOURNE, Australia and INDIANAPOLIS, May 19, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX,...
Lifespan Vision Ventures Leads Violet Therapeutics’ $4.75M Seed Extension Financing
NORWALK, Conn., May 19, 2026 /PRNewswire/ -- Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human healthspan, today announced that it has led Violet Therapeutics' $4.75 million seed extension financing, with participation from Dementia Discovery Fund, UTEC, Ono Venture Investment, and Mass General Brigham Ventures. Violet Therapeutics is...
Millions of ‘pandemic pets’ are reaching midlife, but owners could miss a crucial opportunity to improve their pet’s healthspan
New global research commissioned by ROYAL CANIN® reveals disconnect in how owners understand their pet's ageing with over a third surveyed (38%) believing nothing can be done about it*, while over half (55%) of those surveyed avoid thinking or talking about their pets ageing because it feels too sad.¹ Despite this,...
